Focus Partners Wealth Invests $649,000 in Encompass Health Co. (NYSE:EHC)

Focus Partners Wealth purchased a new stake in Encompass Health Co. (NYSE:EHC - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 7,031 shares of the company's stock, valued at approximately $649,000.

Other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Encompass Health by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company's stock worth $59,544,000 after purchasing an additional 4,345 shares in the last quarter. Merit Financial Group LLC bought a new position in shares of Encompass Health in the fourth quarter worth about $374,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Encompass Health in the fourth quarter worth about $4,160,000. MassMutual Private Wealth & Trust FSB increased its stake in shares of Encompass Health by 87.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock valued at $27,000 after buying an additional 137 shares during the period. Finally, US Bancorp DE increased its stake in shares of Encompass Health by 9.6% in the fourth quarter. US Bancorp DE now owns 1,380 shares of the company's stock valued at $127,000 after buying an additional 121 shares during the period. Institutional investors own 97.25% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on EHC shares. KeyCorp upped their price objective on Encompass Health from $120.00 to $122.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Royal Bank of Canada increased their price target on Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday, April 28th. Wall Street Zen raised shares of Encompass Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday. UBS Group raised their target price on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. Finally, Truist Financial restated a "buy" rating and issued a $135.00 target price (up previously from $116.00) on shares of Encompass Health in a report on Monday, April 28th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $120.86.

Encompass Health Stock Performance

Shares of EHC traded up $0.13 during mid-day trading on Friday, hitting $118.74. The stock had a trading volume of 388,011 shares, compared to its average volume of 699,207. The firm has a market cap of $11.97 billion, a P/E ratio of 26.62, a PEG ratio of 2.31 and a beta of 0.91. The business has a fifty day moving average price of $107.85 and a 200-day moving average price of $101.40. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. Encompass Health Co. has a 52 week low of $82.74 and a 52 week high of $121.96.

Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same period in the previous year, the company posted $1.12 earnings per share. The business's revenue was up 10.6% on a year-over-year basis. On average, equities research analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. The ex-dividend date is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.57%. Encompass Health's payout ratio is 14.05%.

Insider Activity at Encompass Health

In other news, CEO Mark J. Tarr sold 118,384 shares of the company's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the completion of the transaction, the chief executive officer now directly owns 527,070 shares in the company, valued at approximately $64,054,817.10. This represents a 18.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP John Patrick Darby sold 10,000 shares of the company's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the completion of the transaction, the executive vice president now owns 79,710 shares of the company's stock, valued at $9,149,910.90. The trade was a 11.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 132,663 shares of company stock worth $16,034,082. 2.00% of the stock is owned by company insiders.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.